Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Full-year 2025 financial results disclosed via press release (Exhibit 99.1).
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results disclosed via press release (Exhibit 99.1)
- Reporting period: fiscal year ended December 31, 2025
- Press release also includes a business update: likely covers pipeline or clinical trial progress for this clinical-stage oncology company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.